HLA B*15:02, Carbamazepine Sensitivity Build info
Synonyms |
|
||||||||||||||||
Short Name |
HLA B*15:2, CARBAMAZEPINE SENSITIVITY |
||||||||||||||||
Procedure Master Number |
LAB11148 |
||||||||||||||||
Procedure ID |
|||||||||||||||||
Clinical Info |
Use to identify patients who may be at risk for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) prior to treatment with carbamazepine (CBZ). This test has been recommended for patients of Asian descent who are being considered for carbamazepine therapy. The utility of this test for patients of other ethnic backgrounds has not been established. |
||||||||||||||||
Specimen Type |
Blood, Swab |
||||||||||||||||
Container |
Whole blood or buccal swabs |
||||||||||||||||
Collection Instructions |
Container/Tube: Collect 7 mL whole blood (2 Lavender Top Tubes) or 4 buccal swabs |
||||||||||||||||
Transport Instructions |
Maintain whole blood at room temperature or refrigerate. Keep buccal swabs dry and at room temperature |
||||||||||||||||
Specimen Stability |
Room Temperature or Refrigerated |
||||||||||||||||
Methodology |
Sequence-based typing (SBT), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain the required resolution. |
||||||||||||||||
Days Performed |
TAT: 4-8 Days |
||||||||||||||||
Performing Laboratory |
LabCorp |
||||||||||||||||
CPT |
81381 |
||||||||||||||||
PDM |
225706 |
||||||||||||||||
Results |
|